Mirati Therapeutics Growth, Revenue, Number of Employees and Funding
Estimated Revenue & Financials
- Mirati Therapeutics's estimated revenue is currently $12.9M per year.
- Mirati Therapeutics received $130.0M in venture funding in January 2019.
- Mirati Therapeutics's estimated revenue per employee is $140500
- Mirati Therapeutics's total funding is $101.3M.
- Mirati Therapeutics has 92 Employees.
- Mirati Therapeutics grew their employee count by 48% last year.
- Mirati Therapeutics currently has 17 job openings.
|Isan Chen||CHIEF MEDICAL AND DEVELOPMENT OFFICER|
|James Christensen||EXECUTIVE VICE PRESIDENT AND CHIEF SCIENTIFIC OFFICER|
|Sanjeev Sharma||Senior Vice President|
|Tavette Neskorik||Director, Clinical Science|
|Nathan Koons||Associate Director, Clinical Data Management|
|Karen Velastegui||Sr Director, Clinical Science|
|Peter Olson||Director of Research|
|Sudar Alagarsamy||Senior Director Program Management|
|Aaron Burns||Associate Director of Medicinal Chemistry|
What Is Mirati Therapeutics?
Mirati Therapeutics develops molecularly targeted, single agent and immuno-oncology combination therapies intended to treat cancer. Mirati's approach combines the three most important factors in oncology drug development, 1) researching and developing drug candidates that target genetic and epigenetic drivers of cancer, 2) designing creative and agile clinical development strategies that select for patients whose tumors are dependent on specific driver alterations, and 3) leveraging a highly accomplished oncology precision medicine leadership team. The Mirati team uses a blueprint - proven by their prior work - for developing potential breakthrough cancer therapies, with accelerated development paths, in order to improve outcomes for patients. Mirati is advancing three drug candidates through clinical development for multiple oncology indications.keywords:Biotechnology,Healthcare,Marketing,Pharmaceuticals
Number of Employees
Employee Growth %
|Name||Revenue||Number of Employees||Employee Growth||Total Funding|
|Advanced Cell D...||$25.7M||178||8%|
|Full Spectrum A...||$6M||42||5%|
Mirati Therapeutics News
Mirati Therapeutics Inc is a biotechnology company. The company's focuses on precision medicine for oncology therapeutics. The company ...
The shares of Mirati Therapeutics, Inc. (NASDAQ:MRTX), has jumped by 116.74% year to date as of 08/21/2019. The shares currently trade at ...
Leerink Swann set a $118.00 price target on Mirati Therapeutics (NASDAQ:MRTX) in a research report sent to investors on Wednesday, July ...
Mirati Therapeutics Funding
|2013-10-17||$Undisclosed||Undisclosed||Leerink Swann LLC||Article|
Mirati Therapeutics Executive Hires
|2016-01-11||Marcy Graham||VP Investor Relations/Corporate Communications||Article|
|2016-10-05||Chris LeMasters||Executive Vice President/Chief Business Officer||Article|